Correlation Between Structure Therapeutics and Inozyme Pharma
Can any of the company-specific risk be diversified away by investing in both Structure Therapeutics and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Structure Therapeutics and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Structure Therapeutics American and Inozyme Pharma, you can compare the effects of market volatilities on Structure Therapeutics and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Structure Therapeutics with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Structure Therapeutics and Inozyme Pharma.
Diversification Opportunities for Structure Therapeutics and Inozyme Pharma
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Structure and Inozyme is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Structure Therapeutics America and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Structure Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Structure Therapeutics American are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Structure Therapeutics i.e., Structure Therapeutics and Inozyme Pharma go up and down completely randomly.
Pair Corralation between Structure Therapeutics and Inozyme Pharma
Given the investment horizon of 90 days Structure Therapeutics American is expected to generate 1.11 times more return on investment than Inozyme Pharma. However, Structure Therapeutics is 1.11 times more volatile than Inozyme Pharma. It trades about -0.21 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.53 per unit of risk. If you would invest 4,115 in Structure Therapeutics American on September 1, 2024 and sell it today you would lose (800.00) from holding Structure Therapeutics American or give up 19.44% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Structure Therapeutics America vs. Inozyme Pharma
Performance |
| Timeline |
| Structure Therapeutics |
| Inozyme Pharma |
Structure Therapeutics and Inozyme Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Structure Therapeutics and Inozyme Pharma
The main advantage of trading using opposite Structure Therapeutics and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Structure Therapeutics position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |